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ABSTRACT
Exiguobacterium spp. are alkaliphilic, halotolerant,
non-spore-forming Gram-positive bacilli, hitherto
uncharacterised from human infections. Six
isolates of Exiguobacterium aurantiacum were
obtained from patients with bacteraemia, three
of whom had myeloma. All isolates formed
orange–yellow pigmented colonies on blood agar,
were catalase- and DNase-positive, and grew on
nutrient agar at pH 10 and in the presence of
NaCl 6% w ⁄ v. The six isolates were susceptible to
all antimicrobial agents tested and were uniform
in their fatty acid and mass spectrum profiles.
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Coryneform bacteria include a diverse range of
bacterial genera grouped together as aerobic non-
spore-forming Gram-positive bacilli. Of these, the
genus Exiguobacterium was first isolated from
potato-processing effluent in 1983 [1] in the form
of a single species, Exiguobacterium aurantiacum.
Eight other alkaliphilic and halotolerant species
have been described subsequently, namely
Exiguobacterium acetylicum, Exiguobacterium antart-
icum, Exiguobacterium undae, Exiguobacterium oxido-
tolerans, Exiguobacterium aestuarii, Exiguobacterium
marinum, Exiguobacterium mexicanum and Exiguo-
bacterium artemiae [2,3]. A report in 2003 used 16S
rDNA sequence homology to indicate the possible
presence of E. aurantiacum in a patient with
periodontitis [4], and a novel Exiguobacterium sp.
was identified from blood culture in 2006 using
the same technology [5]. The present study
reports the identification of a further six isolates
of E. aurantiacum from blood cultures over a
10-year period. The first case was a male aged
27 years with a history of intravenous drug abuse.
The patient presented to hospital with a swollen
and tender left leg, with cellulitis of the left groin
where he had injected himself 2 days previously.
On the following day, blood samples were taken,
from which Gram-positive yellow-pigmented
colonies were isolated. Three further isolates were
from adult males, two of whom had multiple
myeloma and the third of whom had suspected
infective endocarditis. The fifth case was a neo-
nate. All of these patients responded to therapy
and the organism was not recovered from sub-
sequent specimens.
Full clinical information was available for the
sixth patient, who was a Caucasian male aged
55 years, diagnosed with IgG kappa multiple
myeloma 4 years previously. This patient
received local radiotherapy, corticosteroids and
six courses of infusional chemotherapy via an
indwelling central venous line. During the final
course of chemotherapy, the patient became
febrile (38.2C) and experienced rigors after the
indwelling central line was flushed. The patient
was otherwise well and not neutropenic, and was
therefore treated empirically with intravenous
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ceftazidime and teicoplanin according to the
protocol for fever. The aerobic and anaerobic
blood culture bottles drawn through the central
line yielded Gram-positive bacilli (identified sub-
sequently as E. aurantiacum) and coagulase-
negative staphylococci. Despite treatment with
intravenous ceftazidime and teicoplanin for the
following 3 days, the fever persisted. Peripheral
blood cultures, taken simultaneously, were neg-
ative. Only when the central line was removed on
day 4 did the fever resolve. The isolation of
E. aurantiacum from central, but not peripheral,
blood cultures, together with the temporal
association between line flushing and the onset
of symptoms, supports the diagnosis of an
E. aurantiacum long-line infection. The fact that
the patient’s fever resolved only when the line
was removed is also consistent with this diagno-
sis. Unfortunately, specific details of the line tip
culture were no longer available, and a report of
‘normal skin flora’ was issued.
All isolates grew aerobically on Columbia
blood agar and formed orange–yellow pigmented
colonies 1–1.5 mm in diameter after incubation for
24–48 h at 37C. All six isolates produced catalase
and DNase, and grew on nutrient agar at
pH 10 and in the presence of NaCl 6% w ⁄ v.
Reactions in the API CORYNE kit (bioMe´rieux,
Marcy l’Etoile, France) and in additional bio-
chemical tests indicated a strong similarity to
Cellulomonas ⁄Microbacterium spp. (Table 1). All
isolates were susceptible to ampicillin, cefotaxime,
chloramphenicol, ciprofloxacin, clindamycin,
erythromycin, gentamicin, penicillin, rifampicin,
teicoplanin, tetracycline and trimethoprim
according to Etests (AB Biodisk, Solna Sweden).
Cultures were grown on Trypticase Soya Broth
Agar (BBL, Cockeysville, MD, USA) at 30C for
48 h, after which their long-chain cellular fatty
acids were extracted and analysed by gas chro-
matography (MIDI Sherlock, Newark, NJ, USA).
As shown in Table 2, the major fatty acid peaks
were isoC13:0, anteisoC13:0, C16:0, isoC17:0, and C18:0.
This profile gave a score that was unacceptably
low for identification of E. acetylicum, but
E. aurantiacum was not included in the database.
Of note, the n-alcohol C16:0 values for the six
isolates ranged between 1.09 and 8.62. The type
strain gave a value of 1.98, which could explain the
previous failure of Lopez-Cortez et al. [3] to detect
this fatty acid. Universal primers for 16S rDNA
genes were used to amplify a near complete
fragment using PCR, with subsequent sequencing
revealing high sequence homology (99.2%) with
E. aurantiacum (GenBank).
The patient isolates and the type strain of
E. aurantiacum (NCIMB 11798) were analysed
further by matrix-assisted laser desorption ⁄ ioni-
sation time-of-flight mass spectrometry (MALDI-
TOF-MS). In this particular application of the
method, the surface-associated molecules of the
cell yield a species-specific mass spectral profile
that can be aligned with profiles in an existing
database [6]. All of the isolates matched the
Table 1. Biochemical test results for clinical isolates of
Exiguobacterium aurantiacum
Nitrate v
Pyrazinamidase +
Pyrrolidonyl-arylamidase –
Alkaline phosphatase v
b-Glucuronidase –
b-Galactosidase v
a-Glucosidase +
b-n-Acetyl-glucosaminidase v
Aesculin +
Urease –
Gelatin v
Acid from:
Glucose +
Ribose +
Xylose v
Mannitol v
Maltose +
Lactose –
Sucrose +
Glycogen +
Catalase +
Oxidase –
Casein hydrolysis +
Tween-80 hydrolysis –
Tyrosine (growth) +
Tyrosine (hydrolysis) –
Tyrosine (pigment) –
DNase +
+, positive; –, negative; v, variable.
Table 2. Whole-cell fatty acids of clinical isolates of
Exiguobacterium aurantiacum
Fatty acid E. aurantiacum
isoC11:0 1.05–1.60
isoC12:0 1.05–2.98
C12:0 0.2.20–5.93
isoC13:0 10.39–20.65
anteisoC13:0 5.21–10.95
isoC14:0 0–0.65
C14:0 2.06–6.07
isoC15:0 1.38–6.34
anteisoC15:0 1.17–1.51
n-Alcohol C16:0 1.09–8.62
isoC16:0 0.93–1.62
C16:1 w11c 2.38–15.87
C16:0 15.45–32.65
isoC17:1 w10c 0–0.91
isoC17:0 3.40–11.52
anteisoC17:0 1.23–1.65
C17:0 0.69–0.77
C18:3 w6c (6,9,12) 0–2.46
C16:0 2OH 0.35–0.82
C18:1 w9c 1.08–3.58
C18:0 3.45–11.91
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E. aurantiacum profile, with characteristic mass
ions at 772 and 1379 Da reinforcing this identifi-
cation (Fig. 1).
In recent years, an increasing number of envi-
ronmental saprophytic bacterial species have
emerged that have the capacity to breach envi-
ronmental barriers and cause infection in immu-
nocompromised hosts and individuals at
extremes of age. Although E. aurantiacum has
been recovered from clinical specimens in the
past, it has not hitherto been reported as a cause
of bacteraemia. Three of the six cases described in
the present study had myeloma, which might
indicate that individuals with immunosuppres-
sion are predisposed to infection by E. aurantia-
cum. The species is characteristically extremely
tolerant of alkaline conditions; thus, growth at
pH 10 would appear to be a useful screen to
presumptively classify yellow-pigmented coryne-
forms as E. aurantiacum. Other supportive bio-
chemical characteristics are catalase production,
fermentation of glucose, maltose and sucrose,
aesculin hydrolysis, motility and salt tolerance.
In summary, this report describes the character-
isation of an hitherto unsuspected bacterial species
from cases of bacteraemia, and underlines the need
to examine clinically relevant isolates of obscure
species using a polyphasic taxonomic approach.
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Fig. 1. Mass spectral profiles of two isolates of Exiguobacterium aurantiacum, showing characteristic peaks at 772 and
1397 Da.
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